Related resources
Search for item elsewhere
University researcher(s)
Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma
Hartmann P, Herholz KG, Salzberger B, Petereit H F
Ann. Hematol. 2004;83(4).
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.
Abstract
Department of Internal Medicine I, Division of Infectious Diseases, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany. pia.hartmann@klinik.uni-regensburg.deTemozolomide, a recently approved cytotoxic agent for the treatment of malignant glioma, has shown promising results in the treatment studies published so far. However, cytopenia and related infectious complications have been reported in 2-8% of cases. Here we present three treatment-naive patients with malignant glioma experiencing cytopenia and/or infectious complications after the first cycle of temozolomide. Neutrophils obtained from each patient up to 6 weeks after the end of the temozolomide application showed normal phagocytic capacity but decreased oxygen radical production and thus impairment of microcidal activity. Our data suggest that a prolonged impairment of the immunological defense may occur in temozolomide-treated patients.PMID: 14648028 [PubMed - indexed for MEDLINE]